Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Fig. 1

P&R timelines have been reduced after the inclusion of the TPR. The mean regulatory and P&R times of approved EC ODs from 2003 to 2019 from EC approval to P&R approval in Spain, stratified by before (n = 20) or after (n = 26) the inclusion of the TPR during P&R process in Spain in 2013

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172